Dr. Joseph Barsuglia
17 posts

Dr. Joseph Barsuglia retweetledi

We already had legal psilocybin in 1958.
Sandoz Laboratories, the same company that invented LSD, sold pharmaceutical psilocybin legally throughout the 1960s.
It even had a brand name: 𝘐𝘯𝘥𝘰𝘤𝘺𝘣𝘪𝘯
Doctors prescribed it openly for: depression, anxiety & alcoholism.
2mg pills.
Sold all over the world.
Zero reports of serious complications.
𝗘𝘃𝗲𝗿.
It was removed from the market in 1965, not because of safety data, but because of politics.
Now we're calling it a breakthrough drug.
Same pills. Just 60 years later.

English

@RCarhartHarris Can’t wait to see the difference in the magnitude as a distinct predictor of therapeutic response compared to mystical-type experience, given the longstanding association and findings with MEQ, 5D-ASC, etc.
English

@PaulAustin3w I believe once COMP360 is approved, DEA is not compelled remove all psilocybin from Schedule I. FDA approval is product-specific, not substance-wide. Other psilocybin forms (natural) likely remain Schedule I. Reference Sativex/Cannabis. Illogical scheduling in the first place.
English

If synthetic psilocybin (aka COMP360) is approved for TRD by the end of 2026, most headlines will focus on clinics, psychiatrists, and stock prices.
But this misses the most critical element, IMO.
Approval wouldn’t just validate synthetic psilocybin as a treatment but, more importantly, force a rescheduling conversation at the executive level.
Once the FDA approves psilocybin for TRD, the DEA is legally compelled to move it off Schedule I.
That single step not only reboots U.S. drug policy bbut also:
- Increases state autonomy
- Collapses research costs
- Loosens banking restrictions
- Categories of work previously “underground” or legally ambiguous will surface
Here’s why this matters if you’re considering investing or working in the psychedelic space:
• Demand will outpace access. Even if COMP360 is approved, it’s far from guaranteed that insurance will cover six-hour psychedelic sessions at scale. Approval without accessibility will continue driving people outside traditional medical systems in search of preparation, integration, and ongoing support.
• The work won’t end at symptom relief. Psilocybin opens a critical learning window. What happens in the 2–3 weeks after the experience — lifestyle changes, relational shifts, nervous system regulation, metabolic health — will largely determine whether outcomes last. Most medical practitioners are not trained in the overlap of physiological well-being and mental health. This is a HUGE gap.
• New roles will emerge fast. Education, integration, coaching, facilitation, research, and community-based support aren’t “adjacent” to the clinical model, they’re essential complements to it. The ecosystem will need people who can bridge physiology, psychology, and lived context, not just administer a protocol.
• This is bigger than individual healing. Psychedelics reorganize how people relate to their lives, their bodies, and one another. If we lose that relational and systemic lens, we’ll miss the real promise of this moment.
COMP360 approval would be a medical milestone, one nearly 50 years in the making.
But for those REALLY paying attention, it’s also a career signal.
A signal that the next phase of this work will be built not only in clinics, but in the spaces that help people turn insight into lasting change.
English

Check out my latest article: Is Your “Clean” Nicotine Hardening Your Arteries? What the Vascular Data Actually Show linkedin.com/pulse/your-cle… via @LinkedIn
English
Dr. Joseph Barsuglia retweetledi
Dr. Joseph Barsuglia retweetledi

This may be partially why psychedelic therapy demonstrates transdiagnostic efficacy.
Nicholas Fabiano, MD@NTFabiano
This is a map of repetition among all symptoms in the DSM-5. The majority of symptoms are found across disorders, yet we treat them as separate entities.
English
Dr. Joseph Barsuglia retweetledi

Honored to be interviewed here by @abbierosner Rosner, who has a unique focus on psychedelics, aging, and elderhood.
In Sickness and in Health – Ibogaine’s Promise for the Aging Brain
open.substack.com/pub/abbierosne…
English

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar
Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with a psychedelics mandate.
psychedelicalpha.com/news/matt-zorn…
English

@LauraLoomer @RobertKennedyJr Why would you assume that Matt Zorn called himself that. A news article did. If you are going to be the troll queen at least dont make 1000 assumptions
English

Matt Zorn has been selected by @RobertKennedyJr to be his Deputy General Counsel at HHS.
Zorn is telling drug websites dedicated to mainstreaming psychedelics that he is President Trump’s “psychedelic czar”.
This appears to have been leaked to the press by Zorn without authorization. He even made up a fake title for himself.
Highly doubt the admin would approve of Zorn calling himself “Psychedelics Czar”.
Zorn is listed in the public Health and Human Services Directory as “Deputy General Counsel”.
I guess he will get along with our new shroom eating Surgeon General who isn’t even a licensed doctor.
psychedelicalpha.com/news/matt-zorn…


English

WOW. Concerning new paper by @weldeiry & Zhang finds Covid's spike protein may worsen cancer by disrupting p53 (a tumor suppressor) & its regulator MDM2, impairing anti-cancer gene activation.
This increases cancer cell survival against chemo & may hinder DNA repair. We need spike-clearance/ antiviral strategies to preserve p53’s role!
"...important..not only in the context of viral infection and mRNA vaccines...but also for patients with cancer who may be receiving cytotoxic or other cancer treatments."
Kevin McKernan@Kevin_McKernan
This is one of the most important papers related to spike. It pertains to both C19 and very likely vaccine derived spike. It should offer some humility to those so quick to express a viral peptide in people at unknown dosage and distribution. pubmed.ncbi.nlm.nih.gov/38709242/
English
Dr. Joseph Barsuglia retweetledi

“In this review, we consider 24 studies, which included 705 individuals receiving ibogaine or noribogaine. This review includes two randomized, double-blind, controlled clinical trials, one double-blind controlled clinical trial, 17 open-label studies or case series (including observational or retrospective studies), three case reports, and one retrospective survey.”
sciencedirect.com/science/articl…
English

@DanWhipple_ @RobertKennedyJr @shellenberger We don’t have a lot of knowledge of the ibogaine treatment although we have heard good anecdotal reports. Any links are appreciated!
English

I am the recovery first candidate for Mayor of Seattle 2025. The current model of addiction treatment in Seattle is broken. We can dramatically improve, how and where we offer addiction treatment, and save the city in the process. @RobertKennedyJr @shellenberger
English

@AutismCapital Thousands of Veterans have been treated with ibogaine for PTSD in Mexico. There are multiple papers in the NIH / Pubmed documenting the efficacy of this protocol for PTSD
pubmed.ncbi.nlm.nih.gov/38182784/
pubmed.ncbi.nlm.nih.gov/37734158/
pubmed.ncbi.nlm.nih.gov/38377244/
pubmed.ncbi.nlm.nih.gov/32704581/
English

@teslaownersSV @elonmusk To “preserve the light of consciousness” you would need InnerSpaceX. It’s the other direction.
English











